Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Therapeutic Advances in Medical Oncology · 2025-01 · 17
DOI: 10.1177/17588359251318850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 14.02.2025. Verfasst von Shigeru Tanzawa und 40 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Kayaku.
Abstract (Originalsprache)
Background
The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear.
Objective
We aimed to evaluate the clinical characteristics and survival impact of hypomagnesemia induced by this therapy.
Design
This was a sub-analysis of the retrospective multicenter NINJA study.
Methods
Among the 93 patients enrolled in the NINJA study, this subanalysis included 75 patients with baseline serum magnesium concentrations.
Results
The incidence of grade ⩾2 hypomagnesemia was 18.0% in the patients with normal baseline serum magnesium concentrations and 42.8% in those with low concentrations ( p = 0.073). The discontinuation rates of GCN treatment owing to hypomagnesemia in each group were 0% and 7.1%, respectively ( p = 0.187). The number of necitumumab doses and severity of hypomagnesemia were positively correlated ( r = 0.389, p < 0.001). Patients who developed hypomagnesemia in fewer than 21 days after the first dose of GCN ( n = 12) had significantly poorer progression-free survival (PFS) than those without the condition ( n = 63; median: 4.1 vs 4.4 months, p = 0.048). A similar trend was observed for OS (median: 9.7 vs 15.7 months, p = 0.062). These results were maintained after multivariate analyses (PFS: hazard ratio (HR) 2.46, p = 0.014; OS: HR 2.78, p = 0.021).
Conclusion
GCN as a second-line or later therapy may be tolerable regardless of the patient’s baseline serum magnesium concentration. On the other hand, early serum magnesium reduction with this therapy is associated with a poor prognosis. However, caution should be needed because our results lacked sufficient information for confounding variables other than those analyzed here that may influence the correlation between hypomagnesemia and survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
- Department of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.
- Department of Data Science, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
- Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Okayama, Japan.
- Department of Respiratory Medicine, Ichinomiya Nishi Hospital, Ichinomiya, Aichi, Japan.
ORCID-Profile: Shigeru Tanzawa, Hiroshige Yoshioka, Fumihiko Kinoshita, Akihiko Miyanaga, Satoshi Tetsumoto, Kazuya Nishii
Förderung
- Nippon Kayaku
Zitieren
APA
Tanzawa, S., Yoshioka, H., Misumi, T., Miyauchi, E., Ninomiya, K., Murata, Y., Takeshita, M., Kinoshita, F., Fujishita, T., Sugawara, S., Kawashima, Y., Hashimoto, K., Mori, M., Miyanaga, A., Hayashi, A., Tanaka, H., Honda, R., Nojiri, M., Sato, Y., …, & Seki, N. (2025). Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251318850
Vancouver
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, et al. Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251318850
BibTeX
@article{Tanzawa2025,
author = {Tanzawa, Shigeru and Yoshioka, Hiroshige and Misumi, Toshihiro and Miyauchi, Eisaku and Ninomiya, Kiichiro and Murata, Yasunori and Takeshita, Masafumi and Kinoshita, Fumihiko and Fujishita, Takatoshi and Sugawara, Shunichi and Kawashima, Yosuke and Hashimoto, Kazuki and Mori, Masahide and Miyanaga, Akihiko and Hayashi, Anna and Tanaka, Hisashi and Honda, Ryoichi and Nojiri, Masafumi and Sato, Yuki and Hata, Akito and Ishikawa, Nobuhisa and Kozuki, Toshiyuki and Kawamura, Takahisa and Saito, Go and Yamaguchi, Teppei and Asada, Kazuhiro and Tetsumoto, Satoshi and Tanaka, Hiroshi and Watanabe, Satoshi and Umeda, Yukihiro and Yamaguchi, Kakuhiro and Nishii, Kazuya and Tsuruno, Kosuke and Misumi, Yuki and Kuraishi, Hiroshi and Yoshihara, Ken and Nakao, Akira and Kubo, Akihito and Yokoyama, Toshihiko and Watanabe, Kana and Seki, Nobuhiko},
title = {Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251318850}
}
EUVIMED